BC Extra | Aug 27, 2018
Clinical News

Esperion combo lowers LDL-C in high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
BC Innovations | Oct 3, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Typhoid Cell culture and zebrafish studies suggest inhibiting cholesterol uptake in host cells could help treat Salmonella enterica serovar Typhi infection. In HeLa cells challenged with S. typhi , a tool compound that lowers cholesterol...
BC Extra | Aug 9, 2017
Clinical News

Esperion to raise funds after reporting bempedoic acid LDL-C data

Esperion Therapeutics Inc. (NASDAQ:ESPR) proposed to raise $150 million in a follow-on after market close on Tuesday following its announcement earlier in the day that oral bempedoic acid (ETC-1002)/ Zetia ezetimibe plus Lipitor atorvastatin met...
BC Week In Review | Mar 17, 2017
Company News

Familial Hypercholesterolemia, Express Scripts news

The foundation said it partnered with Express Scripts to expand the PBM’s coverage of familial hypercholesterolemia patients, giving them broader access to PCSK9 inhibitors. Under the PBM's new criteria, patients would qualify for prior authorization...
BC Extra | Mar 15, 2017
Company News

Express Scripts expanding PCSK9 coverage for FH patients

The Familial Hypercholesterolemia Foundation (Pasadena, Calif.) said it partnered with Express Scripts Holding Co. (NASDAQ:ESRX) to expand the PBM’s coverage of familial hypercholesterolemia patients, giving them broader access to PCSK9 inhibitors. Under the PBM's new...
BC Innovations | Jan 26, 2017
Strategy

Deep roots

Regeneron Pharmaceuticals Inc . is starting to see the fruits of its experiment with Geisinger Health System to mine vast quantities of patient data for links between genotype and phenotype. Three years into the project, the...
BC Week In Review | Aug 15, 2016
Clinical News

Bempedoic/ezetimibe: Phase I started

Esperion began a Phase I trial of 180 mg bempedoic acid/10 mg ezetimibe. Esperion Therapeutics Inc. (NASDAQ:ESPR), Ann Arbor, Mich.   Product: Bempedoic/ezetimibe   Business: Endocrine/Metabolic   Molecular target: ATP citrate lyase (ACLY) ; Niemann-Pick...
BioCentury | Nov 24, 2014
Product Development

LDL Does IMPROVE IT

The long-awaited results from the IMPROVE-IT cardiovascular outcomes trial have been hailed as opening the gates for next-generation cholesterol drugs to gain approval on the basis of LDL reductions alone. That may be true. But...
BC Extra | Nov 18, 2014
Clinical News

Vytorin meets CV endpoints in IMPROVE-IT trial

Vytorin ezetimibe/simvastatin from Merck & Co. Inc. (NYSE:MRK) met the primary and all secondary composite endpoints versus Zocor simvastatin alone in the intent-to-treat population of the Phase III IMPROVE-IT trial studying cardiovascular events among patients...
BC Week In Review | Apr 15, 2013
Company News

Kotobuki, Shionogi deal

Kotobuki granted Shionogi exclusive, worldwide rights to develop and commercialize cholesterol absorption inhibitor KT6-971 . Kotobuki will receive an upfront payment and is eligible for milestones and royalties. Shionogi declined to disclose financial details, while Kotobuki...
Items per page:
1 - 10 of 15